Judith N. Steenbergen
About
Judith N. Steenbergen is a scholar working on Infectious Diseases, Epidemiology and Molecular Medicine.
According to data from OpenAlex, Judith N. Steenbergen has authored 74 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Infectious Diseases, 32 papers in Epidemiology and 32 papers in Molecular Medicine. Recurrent topics in Judith N. Steenbergen's work include Antibiotic Resistance in Bacteria (32 papers), Antibiotics Pharmacokinetics and Efficacy (25 papers) and Antimicrobial Resistance in Staphylococcus (22 papers). Judith N. Steenbergen is often cited by papers focused on Antibiotic Resistance in Bacteria (32 papers), Antibiotics Pharmacokinetics and Efficacy (25 papers) and Antimicrobial Resistance in Staphylococcus (22 papers). Judith N. Steenbergen collaborates with scholars based in United States, Netherlands and United Kingdom. Judith N. Steenbergen's co-authors include Arturo Casadevall, Grace M. Thorne, Joshua D. Nosanchuk, Howard A. Shuman, Jeff Alder, Francis P. Tally, Guojun Yuan, Obiamiwe Umeh, Stephen Villano and Stephanie D. Malliaris and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.
In The Last Decade
Judith N. Steenbergen
73 papers receiving 4.3k citations
Hit Papers
Peers
Judith N. Steenbergen
Ian A. Critchley United States
Yingchun Xu China
Niels Frimodt‐Møller Denmark
Wright W. Nichols United States
Jacob Strahilevitz Israel
Jong Hee Shin South Korea
Roberta Fontana Italy
Nicholas A. Kartsonis United States
Jung‐Chung Lin Taiwan
Keigo Shibayama Japan
Citations per year, relative to Judith N. Steenbergen Judith N. Steenbergen (= 1×)
peers
Ian A. Critchley
Countries citing papers authored by Judith N. Steenbergen
Since
Specialization
Citations
This map shows the geographic impact of Judith N. Steenbergen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith N. Steenbergen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith N. Steenbergen more than expected).
Fields of papers citing papers by Judith N. Steenbergen
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Judith N. Steenbergen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith N. Steenbergen. The network helps show where Judith N. Steenbergen may publish in the future.
Co-authorship network of co-authors of Judith N. Steenbergen
This figure shows the co-authorship network connecting the top 25 collaborators of Judith N. Steenbergen. A scholar is included among the top collaborators of Judith N. Steenbergen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith N. Steenbergen. Judith N. Steenbergen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lakota, Elizabeth A., Sujata M. Bhavnani, Lawrence V. Friedrich, et al.. (2023). Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics. Antimicrobial Agents and Chemotherapy. 67(4). e0239721–e0239721.
2.
Bhavnani, Sujata M., Jeffrey Hammel, Elizabeth A. Lakota, et al.. (2023). Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae. Antimicrobial Agents and Chemotherapy. 67(4). e0221321–e0221321.
3.
Torres, Antoni, Lynne Garrity-Ryan, Judith N. Steenbergen, et al.. (2021). Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia. International Journal of Infectious Diseases. 104. 501–509.
4.
O’Riordan, William, Lynne Garrity-Ryan, Anita Das, et al.. (2019). Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. The Lancet Infectious Diseases. 19(10). 1080–1090.
5.
Popescu, Monica, Ismail Mitha, Andrzej Madej, et al.. (2017). A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of IV to Oral Omadacycline to Moxifloxacin for the Treatment of Adult Subjects with CABP (The OPTIC Study). Open Forum Infectious Diseases. 4(suppl_1). S543–S544.
6.
Popejoy, Myra W., David L. Paterson, Daniel Cloutier, et al.. (2016). Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae : a pooled analysis of Phase 3 clinical trials. Journal of Antimicrobial Chemotherapy. 72(1). 268–272.
7.
Tanaka, Sébastien, Judith N. Steenbergen, & Stephen Villano. (2016). Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Bioorganic & Medicinal Chemistry. 24(24). 6409–6419.
8.
Wagenlehner, Flo ri an, Obiamiwe Umeh, Judith N. Steenbergen, Guojun Yuan, & Rabih O. Darouiche. (2015). Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). The Lancet. 385(9981). 1949–1956.
9.
Moise, Pamela, Donald S. North, Judith N. Steenbergen, & George Sakoulas. (2009). Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. The Lancet Infectious Diseases. 9(10). 617–624.
10.
Morgan, Margie, et al.. (2008). In vitro activity of daptomycin against multidrug-resistant Staphylococcus aureus and S. aureus with known virulence factors, including community-acquired methicillin-resistant isolates. Diagnostic Microbiology and Infectious Disease. 61(3). 339–342.
11.
Katz, David, Kimberly C. Lindfield, Judith N. Steenbergen, et al.. (2008). A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. International Journal of Clinical Practice. 62(9). 1455–1464.
12.
Streit, Jennifer M, Judith N. Steenbergen, Grace M. Thorne, Jeffrey Alder, & Ronald N. Jones. (2005). Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis. Journal of Antimicrobial Chemotherapy. 55(4). 574–578.
13.
Steenbergen, Judith N., Jeff Alder, Grace M. Thorne, & Francis P. Tally. (2005). Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. Journal of Antimicrobial Chemotherapy. 55(3). 283–288.
14.
Malliaris, Stephanie D., Judith N. Steenbergen, & Arturo Casadevall. (2004). Cryptococcus neoformansvar.gattiican exploitAcanthamoeba castellaniifor growth. Medical Mycology. 42(2). 149–158.
15.
Nosanchuk, Joshua D., Judith N. Steenbergen, Li Shi, George S. Deepe, & Arturo Casadevall. (2003). Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. Journal of Clinical Investigation. 112(8). 1164–1175.
16.
Steenbergen, Judith N. & Arturo Casadevall. (2003). The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans. Microbes and Infection. 5(7). 667–675.
17.
Casadevall, Arturo, Judith N. Steenbergen, & Joshua D. Nosanchuk. (2003). ‘Ready made’ virulence and ‘dual use’ virulence factors in pathogenic environmental fungi — the Cryptococcus neoformans paradigm. Current Opinion in Microbiology. 6(4). 332–337.
18.
Steenbergen, Judith N., Howard A. Shuman, & Arturo Casadevall. (2001). Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proceedings of the National Academy of Sciences. 98(26). 15245–15250.
19.
Steenbergen, Judith N. & Arturo Casadevall. (2000). Prevalence ofCryptococcus neoformansvar.neoformans(Serotype D) andCryptococcus neoformansvar.grubii(Serotype A) Isolates in New York City. Journal of Clinical Microbiology. 38(5). 1974–1976.
20.
Theeuwes, A.G.M., et al.. (1990). Separation of serum proteins by high-performance gel-permeation column systems. Journal of Chromatography B Biomedical Sciences and Applications. 533. 47–61.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ian A. Critchley Breakdown of academic impact, for papers by Yingchun Xu Breakdown of academic impact, for papers by Niels Frimodt‐Møller Breakdown of academic impact, for papers by Wright W. Nichols Breakdown of academic impact, for papers by Jacob Strahilevitz Breakdown of academic impact, for papers by Jong Hee Shin Breakdown of academic impact, for papers by Roberta Fontana Breakdown of academic impact, for papers by Nicholas A. Kartsonis Breakdown of academic impact, for papers by Jung‐Chung Lin Breakdown of academic impact, for papers by Keigo Shibayama